Black FridayUp to 80% OFF
Novacyt SASNovacyt SASNovacyt SAS

Novacyt SAS

No trades
See on Supercharts
OverviewFinancialsNewsIdeasMindsTechnicalsForecastsSeasonals

Trade ideas

Novacyt ALNOV Graham Mullis, CEO of the Novacyt Group, commented: “Novacyt continues to process COVID-19 tests for current and future demand. We continue to ensure that innovation is at the center of our strategy and that our growing portfolio of COVID-19 tests is available to clients in private and public healthcare facilities to expand existing partnerships and support new partnerships. Throughout the pandemic, the demand for NHS testing has remained a key priority for the company and the award of the contract under the National PHE Microbiology Framework is a testament to our continued commitment. “We believe that our long-term strategy also supports the growth of Novacyt after COVID-19. In particular, our progress and growth potential in the private sector will not only help us maximize the opportunity for COVID-19 testing, but also ensure that we are well positioned, along with technologies and partners, for sustainable growth. beyond COVID-19. We therefore believe that Novacyt is well placed to continue to develop its business transformation. " This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. About the Novacyt Group The Novacyt Group is an international diagnostic company generating a growing portfolio of in vitro and molecular diagnostic tests. Its main strengths lie in the development, marketing, design and manufacture of diagnostic products. The main business units of the Company include the Primerdesign and Lab21 products, providing a wide range of high quality assays and reagents worldwide. The Group directly serves the microbiology, hematology and serology markets as well as its global partners, including large companies.
EURONEXT:ALNOVLong
by wallstreetstocks
Novacyt NCTY what a pump !As you can see from the chart Novacyt had a massive volume inflow in the last 2 days even because of the very good news regarding the uk gov that accepted different NCTY covid tests and even because of the news of the new covid variant. If you check my previous analysis I was waiting for a reversal pattern for quite a while and here we are . Be careful if you intend to enter long now because a +30% in one day in stock definitely need a sort of retracement down and than a push up again. Leave a like or a comment if you want to support me Thanks !
LSE:NCYTLong
by Casciouz
2
ALNOV Novacyt Graham Mullis, Group CEO of Novacyt, commented: “Novacyt is continuing to address COVID-19 testing for both current and future demand. We continue to ensure that innovation is at the centre of our strategy and that our growing portfolio of COVID-19 tests are available to customers in both private and public health settings to expand existing, and support new, partnerships. Throughout the pandemic, NHS testing demand has remained a key priority for the Company and the contract award under the PHE National Microbiology Framework is a testament to our continued commitment. “We believe our long-term strategy also supports the growth of Novacyt post-COVID-19. In particular, our progress and growth potential in the private sector will not only help us maximize the COVID-19 testing opportunity but also ensure we are well placed, with both technologies and partners, for sustainable growth beyond COVID-19. We therefore believe Novacyt is well positioned to continue to build on its business transformation.” This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. About Novacyt Group The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.
EURONEXT:ALNOVLong
by wallstreetstocks
ALNOV NOVACYT Novacyt big fall today, don't worry medium long term still hasn't broken level but keep an eye out for volatility next week we recommend that you buy if you can to the level you think is appropriate, it is a company that in the medium term has high expectations L.E.D Capital Management has investments and has had large investments in ALNOV, continuing to rely on its potential - THIS IS NOT A FINANCIAL ADVICE AT ALL- Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying an extensive range assays and reagents worldwide. HE'S GOT BIG CONTRACTS FOR COVID TESTING. A cordial greeting good investment. In Spain at 9/04/2021 carefully L.E.D
EURONEXT:ALNOVLong
by wallstreetstocks